Plain-English translation of NCT07608835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are trying to understand which blood markers can predict whether immunotherapy will work for people with non-small cell lung cancer. By comparing blood samples with tumor tissue samples from patients at different disease stages, they hope to discover new ways to identify which patients will respond best to immunotherapy treatment.
Currently, doctors cannot easily predict which lung cancer patients will benefit from immunotherapy before starting treatment. This study aims to find blood-based markers that could help doctors choose the most effective treatment for each patient earlier.
You likely qualify if…
You likely don't qualify if…
You will have blood samples and tumor tissue samples collected at the start of the study and again if your cancer progresses. For early-stage lung cancer patients, tissue is obtained during surgery; for advanced cancer patients, samples are collected using minimally invasive techniques like CT-guided biopsy or bronchoscopy. The study will follow you over 7 years at two medical centers, with researchers tracking how your disease responds to treatment.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
France